UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets

Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA

Briefs: Alembic Pharmaceuticals and Relonchem

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union

Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets

Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility

Marksans to acquire Tevapharm's bulk formulations business

Plans to double its manufacturing footprint to bolster the growth

Jawed Zia appointed CEO of Cadila Pharmaceuticals Domestic Prescription Business

A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business

UK MHRA approves Marksans All in One oral solution

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs

Six benefits of Cloud Computing in the pharma industry